[A24-08] Vosoritide (achondroplasia, ≥ 2 years) – Addendum to Project A23-92
Last updated 15.02.2024
Project no.:
A24-08
Commission:
Commission awarded on 09.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Patients with achondroplasia 2 years of age and older whose epiphyses are not closed
Unchanged after addendum: indication of non-quantifiable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A24-08
| Project no. | Title | Status |
|---|---|---|
| A23-92 | Vosoritide (achondroplasia, ≥ 2 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.